Linsey W.
- Country
- Belgium
- Department
- N/A
Research Overview
- A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
- Evaluation of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients with Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, and Systemic Inflammation
Data & Insights
Has run more than one trial at 4 of 253 partner sites.
Specializations
Diabetes Management
This investigator specializes in advancing treatments for Type 2 Diabetes Mellitus, with particular focus on novel therapeutic approaches using innovative medications.
- Glycemic Control Optimization
- Cardiovascular Risk Management in Diabetes
- Treatment Transition Strategies
The research encompasses evaluation of treatment efficacy in diabetes care, particularly examining the impact on cardiovascular outcomes and glycemic control.
Cardiovascular Medicine
The investigator conducts research in cardiovascular risk management, specifically studying major cardiovascular events in diabetic patients.
- Cardiovascular Mortality
- Myocardial Infarction Prevention
- Stroke Risk Assessment
Their work focuses on understanding the relationship between diabetes treatments and cardiovascular outcomes in high-risk populations.
Therapeutic Innovation
The investigator examines treatment optimization strategies in diabetes care, including medication switching and dose escalation protocols.
- Comparative Treatment Efficacy
- Therapeutic Switching Protocols
- Long-term Treatment Outcomes
Research interests include evaluating the effectiveness of transitioning between different diabetes therapeutic agents and their impact on patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.